{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061130","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.369920+00:00","generated_at":"2026-06-08T09:57:32.016547+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sana Biotechnology Q3 2023 GAAP net income $1.0M; cash $268.6M, pipeline data expected 2023-2024","bullets":["Q3 2023 GAAP net income $1.0M driven by $82.6M gain from fair value changes on success payment liabilities.","Cash position $268.6M; expects 2024 operating cash burn below $200M, runway into 2025.","Phase 1 ARDENT trial for SC291 (CD19-directed CAR T) enrolling; initial data expected 2023, more robust in 2024.","CTA submitted for IST of HIP-modified primary islet cells in type 1 diabetes; data expected 2023 and 2024.","IND submitted for SC291 in B-cell autoimmune diseases; SC262 IND on track for 4Q 2023; data expected 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061130","json":"https://secwatch.observer/filing/0000950170-23-061130.json","markdown":"https://secwatch.observer/filing/0000950170-23-061130.md","text":"https://secwatch.observer/filing/0000950170-23-061130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000095017023061130/0000950170-23-061130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000095017023061130/sana-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:57:32.016547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7056b8e9a5c75f8f27fcc13d75fdda6cb5a85588","claim":"Sana Biotechnology, Inc. reported financial results for third quarter 2023.","evidence_excerpt":"On November 8, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770121/000095017023061130/0000950170-23-061130-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}